Status: Recruiting
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Participants needed: 32
Trial details
Phase: Phase 1, Phase 2Age: 13-90Biological sex: AllType: InterventionalSponsor: Vironexis Biotherapeutics Inc.Updated: Aug 6, 2026Locations: 11
Eligibility criteria
Age: Part 1: 18-90 years of age, Part 2: 13-90 years of age [+5]
Hepatoxicity (AST or ALT > 2x upper limit of normal) [+5]